Announced

Amneal Pharmaceuticals to acquire the Baclofen franchise of Saol Therapeutics for $83m.

Synopsis

Amneal Pharmaceuticals, a fully-integrated essential medicines company, agreed to acquire the Baclofen franchise of Saol Therapeutics, a private specialty pharmaceutical company, for $83m. "For over 5 years, the Saol team has worked to reinvigorate the Lioresal® brand and develop new treatment options, like LYVISPAHTM, for patients struggling with spasticity. We are excited to see these products find their new home at Amneal along with many of our team members that have been critical to our success," David Penake, Saol Therapeutics CEO.

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Sort

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US